+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones



Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones



European Journal of Clinical Investigation 38(9): 634-639



Recently it has been postulated that gallbladder mucin hypersecretion observed in the pathogenesis of cholesterol gallstone disease may be induced by biliary lipid peroxidation. Ursodeoxycholic acid treatment reduces mucin concentration and the formation of cholesterol crystals in the gallbladder bile of patients with cholesterol gallstones and this effect might be mediated by a decrease of biliary lipid peroxidation. In a double-blind, placebo-controlled trial patients with symptomatic cholesterol gallstones received either ursodeoxycholic acid (750 mg daily) (n = 10) or placebo (n = 12) 10-12 days prior to cholecystectomy. As a marker for lipid peroxidation malondialdehyde was measured in bile together with mucin concentration. In addition, the mucin secretagogue activity of the individual bile samples was assessed in cultured dog gallbladder epithelial cells. Ursodeoxycholic acid therapy resulted in a significant reduction of lipid peroxidation in bile as determined by the biliary malondialdehyde concentration (1.36 +/- 0.28 vs. 2.05 +/- 0.38 micromol L(-1); P < 0.005) and the malondialdehyde (micromol L(-1))/total bile acid (mmol L(-1)) ratio (0.02 +/- 0.005 vs. 0.06 +/- 0.01; P < 0.001). Furthermore, a decrease in mucin concentrations (0.7 +/- 0.3 vs. 1.3 +/- 0.5 mg mL(-1); P < 0.005) and of the mucin secretagogue activity of gallbladder bile (0.9 +/- 0.2 vs. 2.2 +/- 0.3 times control; P < 0.001) was observed. The reduction of lipid peroxidation and mucin secretagogue activity of gallbladder bile induced by ursodeoxycholic acid treatment may contribute to the beneficial effects of this drug on gallbladder bile composition and symptoms in cholesterol gallstone patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034144890

Download citation: RISBibTeXText

PMID: 18837739

DOI: 10.1111/j.1365-2362.2008.01995.x


Related references

Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity of human bile in cholesterol gallstone disease. Gastroenterology 114(4 Part 2): A548-A549, 1998

Ursodeoxycholic acid reduces mucin concentration in the gallbladder bile of patients with gallstones. Gastroenterology 108(4 Suppl. ): A1169, 1995

Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones. Journal of Hepatology 8(1): 1-6, 1989

Prolonged cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under treatment with low dose ursodeoxycholic acid. Gastroenterology 92(5 Part 2): 1742, 1987

Lipid peroxidation and mucin secretagogue activity in bile of gallstone patients. European Journal of Clinical Investigation 37(9): 731-736, 2007

Ursodeoxycholic acid reduces protein levels and their nucleation promoting activity in gallbladder bile of cholesterol stone patients. Hepatology 22(4 Part 2): 504A, 1995

Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. European Journal of Gastroenterology and Hepatology 16(3): 305-311, 2004

Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones. Tokai Journal of Experimental and Clinical Medicine 7(6): 671-683, 1982

Effect of ursodeoxycholic and chenodeoxycholic acid therapy in patients with cholesterol gallstones on intestinal microflora and its bile-acid-metabolizing activity. Current Microbiology 14(2): 79-84, 1986

Changes in biliary bile acid composition and cholesterol saturation of bile in patients with cholesterol gallstones following treatment with ursodeoxycholic acid. Verhandlungen der Deutschen Gesellschaft für Innere Medizin 83: 501-502, 1977

Influence of ursodeoxycholic acid urso on fasting gallbladder volume and gallbladder emptying in patients with cholesterol gallstones and controls. Gastroenterology 94(5 Part 2): A603, 1988

Effects of lovastatin ls ursodeoxycholic acid udca and ls plus udca on bile lipid composition in patients with cholesterol ch gallstones. Gastroenterology 102(4 Part 2): A319, 1992

Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones. Journal of Gastroenterology 29(1): 47-55, 1994

Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Digestive Diseases & Sciences 44(1): 190-196, 1999

Lipid composition and cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones under choleretic treatment with Febuprol. Zeitschrift für Gastroenterologie 26(5): 275-278, 1988